Design. a national, randomised, comparative clinical trial with two parallel groups. Participants. 23 patients fulfilled the study requirements. Intervention. after a one- or two-week wash-out period, 23 patients were randomized, to a 6-week treatment period. Outcomes. immunological and symptom severity changes and safety. Immunologic outcome assessments were blinded to group assignment. 23 patients were randomized and from 22/23 patients (11 in each group) blood samples were analyzed before and after treatment. Conclusion. Both routes of administration demonstrate immunological and clinical effects, with larger inflammatory and innate immunological effects of the nasal spray route and larger allergen-specific clinical effects of the subcutaneous route, and are safe.
Keyphrases
- end stage renal disease
- clinical trial
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- open label
- placebo controlled
- randomized controlled trial
- prognostic factors
- type diabetes
- adipose tissue
- allergic rhinitis
- oxidative stress
- immune response
- phase ii
- quality improvement
- replacement therapy
- platelet rich plasma